www.flandersbio.be

FLANDERSBIO MATCHMAKING DAY

NEW YORK, NY NOVEMBER 16, 2011

FLANDERS HOUSE, NEW YORK TIMES BLD, 620 8TH AVENUE, 44TH FLOOR, NYC, NY

OVER TEN BELGIUM BASED CORPORATIONS WILL SHOWCASE EXCITING INVESTMENT OPPORTUNITIES. THEY ARE LOOKING FOR PARTNERS TO FURTHER DEVELOP THEIR PRODUCT PIPELINE AND PORTFOLIO.

THEY ARE TYPICALLY LOOKING FOR EQUITY AND/OR DEBT COMMITMENTS RANGING FROM USD$7.5 MILLION UP TO USD$60 MILLION TO FUND FURTHER MARKETING OF APPROVED PRODUCTS, CLINICAL TESTING PHASES (I TO III) AND/OR PRECLINICAL DEVELOPMENTS. THE FIELDS OF ACTIVITY COVER CARDIOVASCULAR DISEASES, CANCER, CNS, DIABETES, ADULT STEM CELLS, INFECTIOUS DISEASES AND DIAGNOSTICS.

Organizer: FlandersBio, the biotech industry representative in Flanders, Belgium. FlandersBio represents

240 life sciences and biotech companies and is the organizer of the largest annual regional

biotech convention in Europe with over 1.000 participants. Belgium will host the international

BioPartnering Europe event in 2012.

Ann Van Gysel, Managing Director

Phone: + 32 9 241 80 41

www.flandersbio.be

www.flandersbio.be

PROGRAM

8.00AM Registration and breakfast buffet

8.30AM Welcome

8.40AM Company pitches

12.00PM Lunch

1.00 PM One-on-one meetings

This is a unique opportunity to get a clear insight in a prosperous European Biotech Cluster .

Please confirm your interest before October 7 by reply email.

www.flandersbio.be

THROMBOGENICS

COMPANY DETAILS

Listed: Euronext Brussels

Business Focus:

ThromboGenics (Euronext Brussels: THR) is a biopharmaceutical company focused on the

development of therapeutics for conditions related to the vascular system, cardiovascular diseases,

visual disorders and cancer. The company plans to show proof-of-concept for its products by taking

them through to completion of Phase II clinical trials. To leverage its expertise, ThromboGenics

selectively forms development and marketing collaborations with experienced partners in the

pharmaceutical industry. Such collaborations can lead to ThromboGenics generating revenues via

milestone payments, as well as royalties on commercial sales.

www.thrombogenics.com

INVESTMENT DETAILS

Activities: Eye diseases, Cardiovascular and Cancer

Pipeline: Phase I and II (ophthalmology, cancer and cardiovascular), phase III - Market ready

(ophthalmology)

www.flandersbio.be

MDXHEALTH

COMPANY DETAILS

Listed: Euronext Brussels

Business Focus:

MDxHealth is a molecular diagnostics company committed to developing novel, accurate, and

informative diagnostic tests for early detection of cancer and for personalizing cancer treatment

decisions.

www.mdxhealth.com

INVESTMENT DETAILS

Activities: Diagnostics & Biomarkers in oncology

Pipeline: Pre-market for lung, colon and prostate cancer

Type of Investment: VC's/Private Equity Funds, Corporate Funds

Modalities: Equity

Investors worked with: LSP, BioInvest, ING, RothSchild

REMARKS

Starting US operations in August 2011

www.flandersbio.be

GALAPAGOS

COMPANY DETAILS

Listed: Euronext Brussels

Business Focus:

Galapagos is a mid-size biotechnology company specialized in the discovery and development of

small molecule and antibody therapies with novel modes-of-action. The Company is progressing one

of the largest pipelines in biotech, with seven clinical and over 50 discovery programs. These internal

R&D programs are performed in parallel to target and drug discovery service activities, enabling the

Company to run a cash-generating hybrid business model.

www.glpg.com

INVESTMENT DETAILS

Activities: Cardiac and Vascular, CNS, Brain, Bone, Joint, Cartilage, Dental, Oncology, Infectious

Disease, Immunology and Inflammation, Endocrinology & Metabolic Disease, Genetic Disorders

Pipeline: 50 discovery and 6 clinical programs (Phase I&II)

Type of Investment: investors willing to take an equity position

Investors worked with: Equity investment managers: biotech specialist investors as well as small

and midcap fund managers

www.flandersbio.be

CRYO-SAVE GROUP

COMPANY DETAILS

Listed: Euronext Amsterdam

Business Focus:

Cryo-Save Group is the leading private family bank of human adult stem cells collected from the

umbilical cord blood at birth in Europe, with more than 185,000 samples stored. The group has never

been, and does not intend to become, involved in the storage or expansion of embryonic stem cells.

It is the fourth largest stem cell storage company in the world by number of samples and has an

estimated 50% share of the European market.

www.cryo-save.com

INVESTMENT DETAILS

Activities: Tissue engineering, Cell therapy, stem cell storage and development

Pipeline: Market

Type of Investment: Corporate funds

Modalities: Equity; USD$ 7.5 -25 Million

Investors worked with: none

REMARKS

Cryo-lip, storage of stem cells from fat tissue, launced in US; currently scouting for US managing

director

www.flandersbio.be

PHARMANEUROBOOST

COMPANY DETAILS

Listed: No

Business Focus:

The company’s primary goal is to significantly improve current therapy targeted against mood and

anxiety disorders. The two front-running proprietary projects (PNB01 and PNB02) are targeted

against depression and schizophrenia, respectively.

www.pharmaneuroboost.com

INVESTMENT DETAILS

Activities: CNS drugs

Pipeline: preclinical (Parkinson, Alzheimers disease and obcessive compulsory disorder), phase I

(Schizophrenia) and phase II (Severe major depressive disorder)

Type of Investment: VC's/Private Equity Funds, Banks, Corporate Funds, Joint Venture Partners

Modalities: Equity, Debt, Convertible Debt; USD$ 77 Million

Investors worked with: KBC PE, Saffelberg Investments, Biovest, Finanima

REMARKS

PNB01: Execution of full non-clinical and clinical program up to NDA as requested by FDA + PNB02:

Prepare for and execute first phase III, pivotal study of PNB02

www.flandersbio.be

PRONOTA

COMPANY DETAILS

Listed: No

Business Focus:

Pronota’s mission is to discover, apply and market a new generation of molecular diagnostics

(protein biomarkers) to profoundly improve the development of innovative treatments for unmet

clinical needs, and to make healthcare more individualized and predictive.

www.pronota.com

INVESTMENT DETAILS

Activities: Diagnostics, Biomarker Research

Pipeline: Pre-market for cardio-renal, pre-eclampsia, sepsis, ovarian cancer

Type of Investment: VC's/Private Equity Funds, Banks, Corporate Funds, Joint Venture Partners

Modalities: Equity, USD$ 11-20 Million

Investors worked with: KBC, Gimv, LSP, MP Healthcare, JJDC, Medsciences, Baekeland

REMARKS

Building contacts for series C round of financing

www.flandersbio.be

ARGEN-X

COMPANY DETAILS

Listed: No

Business Focus:

arGEN-X creates novel, antibody-based medicines with the potential to make a meaningful impact on

patients’ lives. In so doing, it will provide significant value to all of its stakeholders. Its SIMPLE

Antibody™ platform generates an unparalleled functional diversity of human antibody leads which

routinely exhibit gold standard affinities, potencies and expression levels.

www.argen-x.com

INVESTMENT DETAILS

Activities: Biologics, Therapeutic Antibodies

Pipeline: Early development

Type of Investment: VC's/Private Equity Funds, Corporate Funds, Joint Venture Partners

Modalities: Equity, USD$ 9-17 Million

Investors worked with: Forbion Capital Partners, LSP, Credity Agricole PE, KBC-PE

www.flandersbio.be

COMPLIX

COMPANY DETAILS

Listed: No

Business Focus:

Complix develops scaffold therapeutics. An early-stage biotech company developing therapeutic

proteins for inflammation, auto-immune and infectious diseases.

Complix is an early-stage biotech company developing therapeutic proteins for inflammation, auto-

immune and infectious diseases.

www.complix.be

INVESTMENT DETAILS

Activities: Therapeutics

Pipeline: Preclinical development

Type of Investment: VC's

Modalities: Equity

Note – Investors worked with: Vesalius Biocapital, LRM, CRP, Gemma Frisius, Baekeland, Vinnof,

TrustCapital, Credit Agricole-PE

REMARKS

Looking for corporate partnering

www.flandersbio.be

PROMETHERA

COMPANY DETAILS

Listed: No

Business Focus:

Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de

Louvain, that develops innovative treatments based on allogeneic adult stem cell technology.

Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to

treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers.

Biosciences was founded in 2009. The company has completed a 5.3 million euros A-round of funding

complemented by 4M€ of loans and grants from the Walloon region end of October 2009.

www.promethera.com

INVESTMENT DETAILS

Activeties: Treatments based on allogenic adult progenitor cell technology

Pipeline: Early development, about to start Phase I,II

Promethera® Biosciences develops a new cell therapy product using allogeneic stem cells expanded from healthy human

liver tissue: Promethera® HepaStem. The product aims to treat a wide variety of liver genetic and acquired diseases

affecting children and adults. The innovation resides in both the simplicity of the treatment, which doesn’t require radical

surgery (compared to liver transplantation), and in the wide variety of liver pathologies that can be addressed with the

same product. This product has received two orphan drug designations from the European Community for the treatment of

Crigler-Najjar syndrome and the treatment of urea cycle disease. In conjunction, Promethera® Biosciences is developing,

Promethera® HepaScreen, a unique cell model for the pharmaceutical industry to mimic metabolism and detoxification of

new drugs by the human liver. Both products are based on a newly discovered and patented stem cell type: the human

Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC). Promethera is contemplating a EUR 14m capital increase (B-

round) to be placed with a selected group of professional new investors and existing shareholders to finance phase I/II of

clinical trials over the next two years.

Type of Investment: VC's/Private Equity Funds, Corporate Funds, Joint Venture Partners

Modalities: Equity, Convertible Debt; USD$ 7-14 Million

Note – Investors worked with: Vesalius Biocapital, Sopartec, Vives, SRIW, Financiere Spinnoff

Luxembourgeoise, Start-up, LRSP, KMOFIN (LRM), business angels

www.flandersbio.be

ALZPROTECT

COMPANY DETAILS

Listed: No

Business Focus:

The objective of the company is to bring its first drug candidate to the clinic in 2 years. AlzProtect will

develop its candidates up to clinical phase 2a before licensing them to a Pharma partner for further

development and marketing.

www.alzprotect.com

INVESTMENT DETAILS

Activeties: Biotech Pharma, CNS & Brain

Pipeline: Preclinical development

Looking for 4 million Euros to finance our clinical phase 1 (Compound AZP2006), this compound has

shown very exciting anti Alzheimer properties. We are also extending our portfolio toward Parkinson

disease and developing another compound family in Alzheimer.

Type of Investment: VC's/Private Equity Funds, Banks, Corporate Funds, Joint Venture Partners

Modalities: Equity; USD$ 7 Million

Note – Investors worked with: Inovam, Finorpa

www.flandersbio.be

FORMAC PHARMACEUTICALS

COMPANY DETAILS

Listed: No

Business Focus:

Formac Pharmaceuticals has developed three proprietary drug delivery technologies allowing

pharmaceutical companies to rescue poorly soluble bioactive drug candidates and redirect their

development towards value medicines. The FORMAC solubilization technologies can also be applied

for line extension development of clinical drug candidates or established marketed drugs.

www.formacpharma.com

INVESTMENT DETAILS

Activeties: Drug Development, Cardiac and Vascular & Gastrointestinal

Pipeline: Early development

FORMAC is currently developing a silica based drug delivery platform for the immediate release of poorly soluble drugs. The company is looking for funding to conduct research:

- in the field of protein/polypeptide based drug delivery using its silica based drug delivery platform

- in the field of controlled release of poorly soluble drugs

thereby increasing the potential of the platform for a broad range of therapeutic applications.

Type of Investment: VC's/Private Equity Funds, Corporate Funds

Modalities: Equity; USD$ 2 Million

Note – Investors worked with: Allegro, Vinnof, Gemma-Frisius, …

www.flandersbio.be

REMYND

COMPANY DETAILS

Listed: No

Business Focus:

reMYND actively drives the development of disease modifying treatments against Alzheimer’s

disease (AD), Parkinson’s disease (PD), and diabetes, either as a Contract Research Organisation

(CRO) or through its own drug discovery & development (DDD). In 2010, reMYND's CRO has

upgraded its offering, reMYND’s DDD has entered into a strategic collaboration with Roche to

develop first-in-class disease modifiers for AD and PD, and featured in an article in Nature.

www.remynd.com

INVESTMENT DETAILS

Activeties: Small molecules Alzheimer's, Parkinson's and Diabetes

Pipeline: Preclinical development

Type of Investment: VC's/Private Equity Funds, Corporate Funds, Joint Venture Partners

Modalities: Equity

Investors worked with: Gemma Frisius Fund, Arkimedes Fortis

REMARKS

US clients are serviced from Belgium

DAFRA PHARMA R&D

www.flandersbio.be

COMPANY DETAILS

Listed: No

Business Focus:

The foundations of the current Dafra Pharma International structure have been laid by the successful

development and distribution in Africa of malaria treatments based on artemisinin derivatives. On

these stable and through customers recognized and valued foundations, Dafra Pharma built their

entire product diversification program, introducing a strong product portfolio with products from

different therapeutic classes, turning Dafra into a total health care solution provider.

www.dafra.be

INVESTMENT DETAILS

Activeties: Infectious diseases, pharmaceutics, early drug development - anti parasitic/anti-fungal

drug

Pipeline: Phase I & II

Dafra Pharma R&D is currently developping a member of the alkylphosphocholine family

(oleylphosphocholine; OlPC) for a neglected indication called leishmaniasis, but our data support that

the drug can also be used to treat invasive fungal infection. Since 2009, we have developped stable

proprietary oral-solid and injectable formulations of OlPC and performed the EMEA/FDA-compliant

preclinical safety & toxicology package using non-dilutive sources of funding. The drug was shown to

be safe and predicted low risk for first-in-man study. Dafra Pharma R&D is now looking for an

investment to perform Phase I/IIa clinical proof of concept for a specific indication (leishmaniasis or

mycosis) to build value in the molecule. The proposed vehicles for investment are the co-creation of

a new company, project out-licensing, project sale or joint development.

Type of Investment: VC's/Private Equity Funds, Joint Venture Partners

Modalities: Equit; USD$ > 5M

REMARKS

Possible co-creation of a new company depending on funding opportunities